Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
According to data from a prospective study of prostate cancer outcomes conducted by researchers at the Mayo Clinic, the PSA test is “valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer.”
Filed under: Diagnosis, Management, Risk | Tagged: benefit, biopsy, PSA, risk | 3 Comments »
As one might expect, there is an extremely diverse (and conflicting) range of reactions to the USPSTF recommendation that routine PSA testing of uninformed men is not supported by good evidence and should no longer be considered as appropriate “standard” practice unless there has been a prior discussion of the risks and benefits of the [...]
Filed under: Diagnosis, Management, Risk | Tagged: benefit, cost, coverage, PSA, risk, USPSTF | 6 Comments »
If you are among the people in America who agree with one or other of the following two statements, you need an immediate crash course in what approval of a new drug by the U.S. Food & Drug Administration (FDA) does actually mean:
Filed under: Drugs in development, Management, Treatment | Tagged: approval, benefit, FDA, risk | 9 Comments »
Two recent publications have offered evidence that, at 10 and 12 years of follow-up, the potential benefits of surgical treatment for low- and intermediate-risk prostate cancer did not include any impact on overall survival for men of 65 years of age or more at the time of surgery.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: benefit, complication, elderly, localized, outcome, over-treatment, risk, side effect | 2 Comments »
An updated, systematic review just published in Annals of Internal Medicine states that it is impossible to come to any conclusions about the efficacy of radiation therapy compared with active surveillance or watchful waiting for the management of localized prostate cancer because of the absence of any high-quality, comparative data.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: benefit, comparative, localized, outcome, radiation | Leave a Comment »
So Dr. Timothy Wilt presented the initial results of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) at the annual meeting of the AUA yesterday morning. They showed what many of us may have been expecting.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: benefit, observation, outcome, PIVOT, surgery | 15 Comments »
One of the statistical games ongoing since publication of the results of the PLCO and the ERSPC screening trials in the New England Journal of Medicine (nearly 2 years ago) has been the estimation of how many men need to undergo regular PSA-based screening, and how many of those men need immediate treatment, to “save [...]
Filed under: Diagnosis, Risk | Tagged: benefit, mortality, risk, screening | 8 Comments »
Toremifene is a selective estrogen receptor modulator or SERM. Some time ago, its developer (GTx, Inc.) initiated a Phase III clinical trial to investigate whether toremifene at a dose of 80 mg/day lowered risk for new vertebral fractures in prostate cancer patients being treated with androgen deprivation therapy (ADT).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: benefit, fracture, Prevention, risk, toremifene | 2 Comments »
In the UK, a nationally developed, on-line decision support tool known as Prosdex is available and is used by at least some men to help them make decisions about whether they wish to undergo PSA testing.
Filed under: Diagnosis, Risk | Tagged: benefit, con, pro, Prosdex, PSA, risk, testing | 2 Comments »
In 1996, the U.S. Preventive Services Task Force (U.S. PSTF) first issued a report stating that the benefits of screening for prostate cancer were far outweighed by the risks. This report was updated in 2002. As of today, Tuesday August 5, 2008, the U.S. PSTF has issued another updated version of their guidelines on this subject … [...]
Filed under: Diagnosis, Tips | Tagged: adverse effects, benefit, Diagnosis, early detection, risk, screening | 11 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site